Search clinical trials for: AZD9977

Total 34 results

AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
AstraZeneca
Parexel

Completed

A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Cardiovascular Disease

United Kingdom
AstraZeneca

Completed

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

Heart Failure

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

Heart Failure

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
AstraZeneca
Parexel

Completed

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AstraZeneca

Terminated

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Lymphoma | Non-Hodgkin Lymphoma | NHL

United States
AstraZeneca

Completed

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Neoplasms

United States
AstraZeneca

Completed

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Carcinoma | Cancer | Tumors

Japan
AstraZeneca

Completed

A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients

Arrhythmia

Sweden, Norway
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers

Healthy

Sweden
AstraZeneca

Completed

AZD9773 Dose Escalation Study

Severe Sepsis

United States
AstraZeneca

Terminated

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Lymphoma

United States, Canada
AstraZeneca

Terminated

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Completed

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

Healthy Subjects | Pharmacodynamics

United Kingdom
AstraZeneca

Completed

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease (MIRACLE)

Heart Failure | Chronic Kidney Disease

United States, Germany, Italy, Spain, Belgium, Denmark, Thailand, Poland, Canada, Korea, Republic of, Slovakia, Taiwan, Turkey, Ukraine, Japan, Czechia, Hungary, Bulgaria, Russian Federation, Sweden, Lithuania, India
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
AstraZeneca

Terminated

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

Heart Failure

Czechia, Bulgaria, Poland, United Kingdom
AstraZeneca

Terminated

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Healthy Subjects

United States
M.D. Anderson Cancer Center
Novartis

Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid Metaplasia

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
AstraZeneca

Completed

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca
Parexel

Completed

Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
AstraZeneca

Completed

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Sweden, Netherlands
AstraZeneca

Completed

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Rheumatoid Arthritis | Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Germany
AstraZeneca

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

Advanced Solid Malignancies

United States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom

3

Subscribe